Metraipolis › archive › dc_97aee85c2c3a
TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response — Europe PMC PMID:42210306
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42210306
- DOI
- 10.1186/s41065-[numero omesso]-x
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-17T06:40:43.446Z
- SHA-256 of the archived text
3fd6e0bbd01090659c2587640f7645f40a2e47e65bad4035ac57d25c122cb7ef- Stable URL of this page
https://metraipolis.com/documento/dc_97aee85c2c3a
How to cite
TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response — Europe PMC PMID:42210306 — Europe PMC (en), https://europepmc.org/article/MED/42210306 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97aee85c2c3a (Metraipolis archive dc_97aee85c2c3a, sha256 3fd6e0bbd01090659c2587640f7645f40a2e47e65bad4035ac57d25c122cb7ef)
BibTeX
@misc{dc97aee85c2c3a,
title = {TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response — Europe PMC PMID:42210306},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42210306},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97aee85c2c3a; sha256 3fd6e0bbd01090659c2587640f7645f40a2e47e65bad4035ac57d25c122cb7ef},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42210306. Agents can read the archived copy with the MCP tool read_document.